MX2023009833A - Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. - Google Patents

Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas.

Info

Publication number
MX2023009833A
MX2023009833A MX2023009833A MX2023009833A MX2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A MX 2023009833 A MX2023009833 A MX 2023009833A
Authority
MX
Mexico
Prior art keywords
centanafadine
methods
making
same
pharmaceutical formulations
Prior art date
Application number
MX2023009833A
Other languages
English (en)
Spanish (es)
Inventor
Kai Suzuki
Syed Asfar Mateen
Praveen Kumar Mididoddi
Shailly Mehrotra
Susan Elizabeth Shoaf
Salin Gupta
Masahiro Hasegawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2023009833A publication Critical patent/MX2023009833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MX2023009833A 2021-02-23 2022-02-22 Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. MX2023009833A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152826P 2021-02-23 2021-02-23
US202163241839P 2021-09-08 2021-09-08
PCT/JP2022/007314 WO2022181625A1 (en) 2021-02-23 2022-02-22 Centanafadine pharmaceutical formulations, and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2023009833A true MX2023009833A (es) 2023-09-04

Family

ID=80735736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009833A MX2023009833A (es) 2021-02-23 2022-02-22 Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas.

Country Status (11)

Country Link
US (6) US11564885B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297734A1 (cg-RX-API-DMAC7.html)
JP (2) JP7787190B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230152046A (cg-RX-API-DMAC7.html)
AU (1) AU2022227367A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015272A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205786A1 (cg-RX-API-DMAC7.html)
IL (1) IL303767A (cg-RX-API-DMAC7.html)
MX (1) MX2023009833A (cg-RX-API-DMAC7.html)
TW (1) TW202302086A (cg-RX-API-DMAC7.html)
WO (1) WO2022181625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302086A (zh) * 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法
EP4577195A1 (en) * 2022-08-24 2025-07-02 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising centanafadine
AU2023335210A1 (en) * 2022-09-02 2025-02-13 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
WO2025183181A1 (en) 2024-02-28 2025-09-04 Otsuka Pharmaceutical Co., Ltd. Use of centanafadine in treatment of adhd symptoms
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006133349A2 (en) 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
ES2529455T3 (es) * 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
RU2015106672A (ru) 2012-07-27 2016-09-20 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения
EP3080080A4 (en) 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
EP3069715A1 (en) * 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
US20180008575A1 (en) 2016-07-11 2018-01-11 Neurovance, Inc. Methods of treating binge eating disorder
TW202302086A (zh) * 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法

Also Published As

Publication number Publication date
US20230338293A1 (en) 2023-10-26
US20230104529A1 (en) 2023-04-06
US11759426B2 (en) 2023-09-19
CA3205786A1 (en) 2022-09-01
US11980690B2 (en) 2024-05-14
AU2022227367A1 (en) 2023-08-03
AU2022227367A9 (en) 2024-10-17
KR20230152046A (ko) 2023-11-02
US20220265557A1 (en) 2022-08-25
US12156941B2 (en) 2024-12-03
JP2024506595A (ja) 2024-02-14
US20240165030A1 (en) 2024-05-23
EP4297734A1 (en) 2024-01-03
JP2025183214A (ja) 2025-12-16
BR112023015272A2 (pt) 2023-11-07
US20250319030A1 (en) 2025-10-16
IL303767A (en) 2023-08-01
JP7787190B2 (ja) 2025-12-16
US12370144B2 (en) 2025-07-29
TW202302086A (zh) 2023-01-16
US11564885B2 (en) 2023-01-31
WO2022181625A1 (en) 2022-09-01
US20250041225A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12020550341A1 (en) Niraparib formulations
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2023011326A (es) Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
BR112023015272A2 (pt) Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
MX2025010194A (es) Formas cristalinas de estado solido de un modulador selectivo de canales de potasio
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2025000572A (es) Formulaciones de capsula de cubierta blanda y metodos de preparacion y uso de las mismas
NO20060991L (no) Feksofenadinsammensetning og fremgangsmate til fremstilling
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2025008658A (es) Composiciones farmacéuticas de propelente ecológico
MX2025012658A (es) Composicion farmaceutica que contiene oseltamivir
PH12022550430A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
WO2026015623A3 (en) Pharmaceutical formulations comprising dydrogesterone and methods of preparation thereof
MX2025010834A (es) Formulaciones de un profarmaco antiviral
MX2023013144A (es) Tableta erosionable.
PE20220381A1 (es) Formulacion de tableta vaginal
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
CO2019011299A2 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4
MX2024004013A (es) Composiciones liquidas orales de enzalutamida.
MX2019008847A (es) Profarmacos de cisteamina.